Carprodyl Quadri 50 mg tablets for dogs

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Carprofen

Available from:

Ceva Santé Animale

ATC code:

QM01AE91

INN (International Name):

Carprofen

Dosage:

50 mg/tablet

Pharmaceutical form:

Tablet

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Dogs

Therapeutic area:

carprofen

Therapeutic indications:

Not Currently Available

Authorization status:

Authorised

Authorization date:

2017-03-24

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprodyl Quadri 50 mg tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE: One tablet contains:
Carprofen.................................................................
50 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
Clover-shaped scored beige tablet
The tablet can be divided into four equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In the dog:
Reduction of inflammation and pain caused by musculo-skeletal
disorders and degenerative joint disease.
As a follow-up to parenteral analgesia in the management of
post-operative pain.
4.3 CONTRAINDICATIONS
Do not use in pregnant and lactating bitches.
Do not use in dogs aged less than 4 months in the absence of specific
data.
Do not use in cats.
Do not use in dogs, suffering from cardiac, hepatic or renal disease,
when there is a possibility of gastrointestinal
ulceration or bleeding or where there is evidence of blood dyscrasia.
Do not use in case of hypersensitivity to the active substance, to
other NSAIDs and to any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
See sections 4.3 and 4.5.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_4_
_/_
_0_
_3_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_7_
_4_
_3_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PR